
usd pm et
summari lead manufactur gener pharmaceut produc broad rang tradit
specialti drug sold around world
price-to-earnings oper ep
oper typic drug develop risk includ
uncertainti stem program
regulatori approv process competitior challeng
patent addit legal risk stem on-going
govern investig opioid sale practic
alleg collabor price risk partial
off-set divers gener portfolio product
account revenu
sale come outsid also think
better posit competitor due
success track record first-gener approv
fiscal year end dec ep estim base cfra
oper earn histor earn report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
pm stock trade
sale fell led
reduct north america sale
total europ rest world
show solid growth howev
share come sever pressur
year due on-going weak
 gener sale think sign
stabil emerg
move averag fda gener applic
consider
think lead
indic lower competit gener
year ahead
gener biosimilar drive sale
growth driver includ
grow market share gener copaxon
approv new biosimilar
gener advair asthma
ramp new product
compet entrench brand
requir increas market spend gain
prescript share think hurt ep
ultim lead sustain
long-term growth also reduc debt
expect
effort continu
think share attract valu
due histor low valuat
expect sustain long-term earn
activ fda declin
sever competitor pull
back industri indic us
competit decreas think
tailwind
kept steadi focu
recent gener downturn avoid
drastic cut asset sale execut
competitor long-term focu
begin pay less competit
left market ramp new gener
 biosimilar version multi-billion
gadvair bneulasta bherceptin like
strategi target complex
high-barri brand drug like
tradit gener maker struggl
target price ep estim
-- histor forward price-to-earnings averag
see downstream consolid remain
price headwind risk view includ
sever gener price deflat advers legal
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor profil mylan nv develop licens manufactur market gener drug
biosimilar brand-nam drug over-the-count over-the-counter medicin varieti therapeut
categori approxim market product world-wide custom approxim
countri territori
compani oper three segment north america europ rest world
market compani manufactur sell divers portfolio drug variou form includ oral
solid inject transderm patch gel cream ointment develop drug across varieti
cardiovascular gastroenterolog diabet oncolog diabet among other
product epipen auto-injector use treatment sever allerg reaction
epinephrin auto-injector sold intern anaphylaxi sever allerg
reaction may caus death either swell shut airway signific drop
blood pressur compani launch first author gener epipen auto-injector
drug formul devic function brand-nam product
compani launch gener version copaxon indic relaps form multipl
sclerosi approv gener copaxon requir lengthi patent litig competitor teva
major victori brand drug gener sale
corpor strategi key object capit diversif across mani therapeut
area well across global geographi also plan focu difficult-to-develop gener
specialti pharmaceut well achiev greater economi scale manufactur
compani also seek first gener firm penetr new market captur new product
opportun obtain first-to-fil statu exclus
impact major develop face sever investig relat
price epipen auto-injector compani best sell product octob ceo
heather bresch testifi front congress regard epipen price shortli afterward januari
feder trade commiss file anti-trust investig whether violat anti-trust
law protect epipen competit august reach deal depart
justic regard epipen paid million settlement alleg overcharg
govern epipen misclassifi gener drug avoid pay medicaid rebat result
signific pressur congress consum media launch gener epipen
decemb price discount brand epipen
octob presid rajiv malik identifi target expand lawsuit alleg
price collus across gener drug industri
august acquir sweden-bas meda ab billion inclus net debt believ
meda brand over-the-counter busi specialti drug franchis includ dermatolog respiratori allergi
along strength differ geograph region includ china russia asian countri
provid signific intern growth opportun
market profil world-wide gener drug market estim billion
account global drug market gener market boost recent year
rise demand inexpens gener throughout world larg number brand drug
recent lost patent protect allow gener competit gener account
prescript dispens repres total
pharmaceut sale dollar accord iqvia reflect much lower price gener versu
financi trend sale aid sever acquisit rose billion billion
repres three-year compound annual growth rate compound-annual-growth-rate howev sale fell
versu advers impact sever gener drug price deflat due intens
competit consolid downstream custom adjust pre-tax incom per share grew
declin repres three-year compound-annual-growth-rate
despit challeng environ gener drug maker recent year leverag
maintain safe level view debt-to-ebita earn interest tax
amort averag ebita-to-interest averag better gener
chairman board
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli under-valued usd
bullish sinc februari technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook pharmaceut sub-industri
next year posit reflect
strong novel drug approv nda activ
food drug administr fda --
posit brand drug maker
repres lion share
improv gener profit margin
competit appear moder
overal posit view somewhat temper
expect lower growth overal
expect strong pace nda continu
next year aid continu robust
growth invest led major brand drug
compani banner year nda
fda new drug approv
repres surg approv compar
mani
new drug littl competit
provid tailwind brand drug
maker strong growth spend
primari driver novel approv uptick
industri increas
estim pace anoth year
growth septemb
growth mark rapid acceler
averag annual growth
side sub-industri
outlook earn growth gener
maker posit closer neutral fda
gener approv total
mani
compet version gener enter
sever gener
price deflat becam norm profit margin
contract surprisingli number
firm announc asset divestitur exit
 gener industri
bright side think lower competit
start impact note gener
approv tick vs
first materi declin least six
year also note move
averag gener applic lead
think anoth sign
mitig competit allow
moder gener deflat
modest improv gener profit margin
year ahead
anoth boost gener maker
record year fda first-gener approv
experienc
first-gener typic enter
market materi lower price
brand-nam counterpart allow
quick market share gain accordingli
major increas first-gener provid
revenu tailwind gener maker next
mitig posit outlook
sub-industri expect slower
prescript volum growth next
year strong gain health-insur
popul driven solid employ
growth view
think gain harder come
 approach full employ
remov tailwind prescript
volum growth assum
slower growth health plan roll gener
mean slower growth prescript volum
versu rise composit
drop
year date januari pharma
slip gain
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et cfra keep hold opinion share nv
keep target line peer
forward ep estim ep vs
estim receiv fda form cite violat
morgantown wv plant began remedi program restructur
includ workforc reduct discontinu product aim
reduc complex facil lower ep estim
ep estim revenu fell sale north america
fell mainli lower epipen sale affect on-going suppli interrupt
discontinu certain product lower price said evalu
wide rang altern think share under-valued
give timet assur altern implement
uncertain much interest may attract given signific price eros
gener epipen sale declin /jeffrey loo cfa
announc yesterday june fda identifi
minor defici myl gener version glaxosmithklin
gsk advair disku asthma drug inhal combin
second time set back fda advair gener
expect fda relay complet respons letter june
provid addit detail must resolv said minor
defici unclear long take address minor
defici think possibl approv push back
marketweight overweight cfra lower
 sector marketweight overweight cite
overhang high drug price continu advers impact sale
growth profit increas influenc third parti payer
expect increasingli limit market access drug deem
expens also due repeal individu mandat compon
cbo expect sever million peopl opt obtain insur
advers trickle-down effect pressur hospit bottom
analyst research note compani news
et cfra maintain strong buy opinion share
lower target ep
estim -- histor forward price-to-earnings averag due price
headwind custom consolid drop ep estim
ep vs
consensu sale fell yoy driven declin north
america total lower volum continu gener price deflat
expect long-term invest complex gener biosimilar start
pay year howev forecast sale growth sever
new product ramp though requir increas
market spend gain share think hurt ep
ultim produc attract long-term growth market current
undervalu prospect view estim free
cash flow yield attract today market cap expect
grow substanti start /colin scarola
pm et cfra upgrad opinion share strong buy
buy keep target
ep estim histor forward price-to-earnings averag due continu
headwind custom consolid risk govern investig
maintain ep estim believ
well-posit benefit potenti stabil gener
drug market recent peak around januari
six-month move averag fda gener drug applic fell
novemb latest data think result competitor scale back
gener oper could lead improv margin next two
year also expect gener industry-averag ep growth due
strategi focus gener biosimilar develop complex
high-barri brand drug sustain margin growth prospect
adequ margin safeti legal risk also exist view given
et cfra upgrad opinion share buy hold
keep target ep
estim histor averag forward price-to-earnings near see
continu challeng custom consolid risk multipl
govern investig maintain ep estim
initi share current low due struggl
last two year loss epipen price power gener price
deflat regulatori problem manufactur site think worst
day howev forecast improv profit margin
competit gener industri appear mitig fda gener
approv track decreas mark first declin sinc
think lead potenti turnaround industri earn
remain focus downturn mani
competitor pull back also see adequ margin safeti legal
risk given histor low valuat /colin scarola
rais target ep
estim -- histor averag forward price-to-earnings see volum
price pressur continu ep vs
consensu keep ep estim drop
sale yoy led north america na total
drop yoy drop na sale mainli due lower volum relat
fda remedi action requir morgantown wv product site well
increas competit epipen adj oper margin improv howev
mainli reduct sg expens
reduct expens adj pre-tax incom yoy
remain cautiou share yet convinc declin
revenu trend stabil note see stabil
gener price environ think deflat may continu
/colin scarola
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share
declin usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
